Trial Profile
An Open Label, Registry Study of the Safety of Iluvien 190 Micrograms Intravitreal Implant in Applicator
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2022
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms IRISS
- Sponsors Alimera Sciences
- 28 Apr 2022 According to a Alimera Sciences media release, data from this trial will be presented at the annual Association for Research in Vision and Ophthalmology (ARVO) conference 2022.
- 23 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2020.
- 23 Oct 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2020.